Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Karyopharm Therapeutics Inc
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AstraZeneca
National Cancer Institute (NCI)
AstraZeneca
Merck Sharp & Dohme LLC
BioNTech SE
Eisai Inc.
Charles University, Czech Republic
GlaxoSmithKline
Genmab
Daiichi Sankyo
Merck Sharp & Dohme LLC
Karyopharm Therapeutics Inc
Queensland Centre for Gynaecological Cancer
Gustave Roussy, Cancer Campus, Grand Paris
Gilead Sciences
AstraZeneca
ARCAGY/ GINECO GROUP
Sichuan Cancer Hospital and Research Institute
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
UNICANCER
Mario Negri Institute for Pharmacological Research
Tufts Medical Center
Hutchmed
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Merck Sharp & Dohme LLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
University of Virginia
Huazhong University of Science and Technology
University of Kentucky
UMC Utrecht
Advenchen Laboratories, LLC
EQRx International, Inc.
Leiden University Medical Center
Leiden University Medical Center
Samsung Medical Center
Institut de Cancérologie de Lorraine
Peking Union Medical College Hospital
Ruhr University of Bochum
Radiation Therapy Oncology Group
Leiden University Medical Center
Radiation Therapy Oncology Group
Ciusss de L'Est de l'Île de Montréal
Queensland Centre for Gynaecological Cancer
Alliance for Clinical Trials in Oncology